Baseline echocardiographic characteristics of patients enrolled in the randomized investigation of MitraClip device in heart failure (RESHAPE HF-2) trial: comparison with COAPT and Mitra-FR
HTML: 4
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: The RESHAPE-HF2 trial is aimed at evaluating the efficacy of the MitraClip device for the treatment of clinically significant functional mitral regurgitation (FMR) in patients with heart failure (HF). This report describes the baseline echocardiographic characteristics of patients enrolled in the RESHAPE-HF2 trial compared to those enrolled in the COAPT and MITRA-FR trials.
Methods: The RESHAPE-HF2 study is a prospective, randomized, multicenter trial involving patients with symptomatic HF, a left ventricular ejection fraction (LVEF) between 20% and 50%, and moderate-to-severe or severe FMR who are ineligible for isolated mitral valve surgery, despite receiving guideline-directed therapy. Patients were randomized 1:1 to either receive the MitraClip or be placed in a control group without the intervention.
Results: For the 505 patients randomized (mean age 70 years, 20% female, mean body mass index 26.8 kg/m2), the mean LVEF in the cohort was 31±8%. The mean regurgitant volume was 37±12 mL, while mean proximal iso-velocity surface area (PISA) radius was 0.72 cm. Less than half of the patients (44%) had MR severity grade 4+. The mean effective regurgitant orifice area (EROA) among patients in RESHAPE-HF2 (0.25 cm2) was lower compared to patients in MITRA-FR (0.31 cm2) and in COAPT (0.40 cm2) trials. Regurgitant volumes in RESHAPE-HF2 were 18% lower than in than in MITRA-FR (45 mL) but 38% higher than in COAPT (27 mL). The mean LV end-diastolic volumes values in the RESHAPE-HF2, COAPT, and MITRA-FR trials were 211 mL, 193 mL, and 250 mL, respectively. Patients in RESHAPE-HF2 (41 mmHg) had a comparatively lower right ventricular systolic pressure than patients in MITRA-FR (54 mmHg) and in COAPT (44 mmHg). Patients in RESHAPE-HF2, MITRA-FR, and COAPT had a similar LVEF of around 31%.
Conclusions: The baseline echocardiographic characteristics of patients in the RESHAPE-HF2 trial differ from patients in the MITRA-FR and COAPT trials. Patients enrolled in RESHAPE-HF2 had moderate-to-severe FMR, characterized by a smaller PISA radius, a lesser proportion of MR severity grade of 4+, and lower mean EROA and regurgitant volumes compared to patients in COAPT and MITRA-FR trials. LVEF was largely similar across all trials. RESHAPE-HF2 is testing TEER in a third distinct cohort of patients who have less severe FMR compared to patients in COAPT trial but have high left atrial volumes. The RESHAPE-HF2 population is also echocardiographically different from the MITRA-FR cohort.
Altmetrics
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Maryanne Caruana, Philip Moons, Adrienne H. Kovacs, Koen Luyckx, Corina Thomet, Werner Budts, Maayke Sluman, Katrine Eriksen, Mikael Dellborg, Malin Berghammer, Bengt Johansson, Alexandra Soufi, Edward Callus, Victor Grech, Silke Apers, Quality of life in Maltese adults with congenital heart disease: a second look , Global Cardiology: Vol. 2 No. 1 (2024)
- Camila Bedo, Juan C. Grignola, Preferential vasodilator effects of levosimendan in resistance pulmonary arteries in a rodent pulmonary embolism model , Global Cardiology: Vol. 2 No. 1 (2024)
- Emanuele Monda, Giuseppe Limongelli, Unveiling the genetic aetiology of non-genetic dilated cardiomyopathy , Global Cardiology: Vol. 2 No. 4 (2024)
- Petros Fountoulakis, Aikaterini Siama, Aimilianos Kalogeris, Marianthi Iliopoulou, Athanasios Tsoukas, Athanasios Manolis, Tricuspid valve fungal endocarditis in a patient with breast cancer and an implantable chemotherapy venous access port , Global Cardiology: Vol. 1 No. 1 (2023)
- Marc Atzenhoefer, Elizabeth Dille, Rebecca Steinke, Nicole Weigert, Keri Sabel, Kirsten Rasmussen, Bridging the gap between study outcomes and real-world results. Algorithm-driven management in a rural cardioMEMS population , Global Cardiology: Vol. 3 No. 1 (2025)
- Asija Začiragić, Marija Mikić, Amela Dervišević, Orhan Lepara, Nesina Avdagić, Nermina Babić, Almir Fajkić, Amina Valjevac, Neck-to-height ratio in Bosnian university students according to the 2017 American College of Cardiology/American Heart Association guidelines on hypertension classification , Global Cardiology: Vol. 2 No. 1 (2024)
- Hussein H. Khachfe, Marwan M. Refaat, Bibliometric analysis of cardiovascular disease research activity in the Arab world , Global Cardiology: Vol. 2 No. 2 (2024)
- Writing Task Force | iCARDIO-Alliance, Draft Document for Public Consultation: iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025 , Global Cardiology: Vol. 2 No. 4 (2024)
- Stefan Peters, Encasement of the left anterior descending coronary artery: association with Takotsubo syndrome, and diagnostic and therapeutic options , Global Cardiology: Vol. 1 No. 1 (2023)
- Shiva Seyed Mokhtassi, Nika Majidi, Yousuf Salmasi, Akhil Sonecha, Sanjay Agrawal, Mubassher Husain, Diana Garcia, Jerry Mitchell, Espeed Khoshbin, How organ care system saved the day during a donation after circulatory death heart transplant: a case of complicated sternal re-entry , Global Cardiology: Vol. 3 No. 1 (2025)
You may also start an advanced similarity search for this article.
